

DOCKET NO.: CP 380F  
Application No.: 10/776,504  
Office Action Dated: January 24, 2007

PATENT  
REPLY FILED UNDER EXPEDITED  
PROCEDURE PURSUANT TO  
37 CFR § 1.116

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1. (Currently Amended) A method of treating ~~acute myeloblastic leukemia~~, acute myelomonocytic leukemia, ~~acute monocytic leukemia~~, or acute erythroleukemia in a human, which comprises administering to the human a combination of (i) a therapeutically effective amount of arsenic trioxide, and (ii) all-trans retinoic acid.
2. (Canceled)
3. (Previously Presented) The method of claim 1, wherein the arsenic trioxide is formulated as an ionic aqueous solution.
4. (Previously Presented) The method of claim 1, wherein the total daily amount administered of the arsenic trioxide is from about 10 µg to about 200 mg.
5. (Previously Presented) The method of claim 1, wherein the total daily amount administered of the arsenic trioxide is from about 0.5 mg to about 150 mg.
6. (Previously Presented) The method of claim 1, wherein the total daily amount administered of the arsenic trioxide is from about 0.5 mg to about 70 mg.
7. (Previously Presented) The method of claim 1, wherein the arsenic trioxide is administered parenterally.
8. (Previously Presented) The method of claim 1, wherein the arsenic trioxide and the all-trans retinoic acid are administered intravenously.
9. (Previously Presented) The method of claim 1, wherein the all-trans retinoic acid and the arsenic trioxide are administered in combination with an effective amount of at least one further therapeutic agent.

DOCKET NO.: CP 380F  
Application No.: 10/776,504  
Office Action Dated: January 24, 2007

PATENT  
REPLY FILED UNDER EXPEDITED  
PROCEDURE PURSUANT TO  
37 CFR § 1.116

10. (Original) The method of claim 9, wherein the further therapeutic agent is a chemotherapeutic or radiotherapeutic.
11. (Previously Presented) The method of claim 9, wherein the further therapeutic agent is selected from the group consisting of etoposide, cisplatin, carboplatin, estramustine phosphate, vinblastine, methotrexate, hydroxyurea, cyclophosphamide, doxorubicin, 5-fluorouracil, taxol, diethylstilbestrol, VM-26(vumon), BCNU, procarbazine, cytokines, therapeutic vaccines, and immunomodulators.
- 12-18. (Canceled)
19. (Previously Presented) The method of claim 1, wherein the cancer has metastasized.
20. (Previously Presented) The method of claim 1, wherein the all-trans retinoic acid is administered prior to the arsenic trioxide.
21. (Previously Presented) The method of claim 1, wherein the all-trans retinoic acid is administered after the arsenic trioxide.
22. (Previously Presented) The method of claim 1, wherein the all-trans retinoic acid and the arsenic trioxide are administered concurrently.
23. (Canceled)
24. (Previously Presented) The method of claim 1, wherein the cancer is refractory.